Biondo Investment Advisors LLC Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

Biondo Investment Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 867.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,461 shares of the biopharmaceutical company’s stock after purchasing an additional 7,586 shares during the quarter. Biondo Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $5,366,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of REGN. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Costello Asset Management INC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Tompkins Financial Corp acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. Finally, Curat Global LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $589.48 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market capitalization of $62.48 billion, a P/E ratio of 14.86, a P/E/G ratio of 1.99 and a beta of 0.33. The business’s 50-day moving average is $550.48 and its two-hundred day moving average is $592.20. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the company earned $11.56 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 3.6% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Analyst Ratings Changes

REGN has been the topic of several research reports. Morgan Stanley reissued an “overweight” rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research note on Monday, August 4th. Guggenheim increased their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Canaccord Genuity Group reissued a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Finally, UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $829.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.